These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

793 related items for PubMed ID: 26107510

  • 1. Effect Modifying Role of Serum Calcium on Mortality-Predictability of PTH and Alkaline Phosphatase in Hemodialysis Patients: An Investigation Using Data from the Taiwan Renal Registry Data System from 2005 to 2012.
    Lin YC, Lin YC, Hsu CY, Kao CC, Chang FC, Chen TW, Chen HH, Hsu CC, Wu MS, Taiwan Society of Nephrology.
    PLoS One; 2015; 10(6):e0129737. PubMed ID: 26107510
    [Abstract] [Full Text] [Related]

  • 2. Comparative mortality-predictability using alkaline phosphatase and parathyroid hormone in patients on peritoneal dialysis and hemodialysis.
    Rhee CM, Molnar MZ, Lau WL, Ravel V, Kovesdy CP, Mehrotra R, Kalantar-Zadeh K.
    Perit Dial Int; 2014; 34(7):732-48. PubMed ID: 24385335
    [Abstract] [Full Text] [Related]

  • 3. Risk factors and risk for mortality of mild hypoparathyroidism in hemodialysis patients.
    Guh JY, Chen HC, Chuang HY, Huang SC, Chien LC, Lai YH.
    Am J Kidney Dis; 2002 Jun; 39(6):1245-54. PubMed ID: 12046038
    [Abstract] [Full Text] [Related]

  • 4. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis.
    Nasri H, Baradaran A, Naderi AS.
    Acta Med Austriaca; 2004 Aug; 31(3):67-72. PubMed ID: 15515479
    [Abstract] [Full Text] [Related]

  • 5. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis.
    Nasri H, Baradaran A.
    J Ayub Med Coll Abbottabad; 2004 Aug; 16(2):3-8. PubMed ID: 15455608
    [Abstract] [Full Text] [Related]

  • 6. Effect of bone mineral guideline target achievement on mortality in incident dialysis patients: an analysis of the United Kingdom Renal Registry.
    Tangri N, Wagner M, Griffith JL, Miskulin DC, Hodsman A, Ansell D, Naimark DM.
    Am J Kidney Dis; 2011 Mar; 57(3):415-21. PubMed ID: 21131115
    [Abstract] [Full Text] [Related]

  • 7. Relationship between the serum parathyroid hormone and magnesium levels in continuous ambulatory peritoneal dialysis (CAPD) patients using low-magnesium peritoneal dialysate.
    Cho MS, Lee KS, Lee YK, Ma SK, Ko JH, Kim SW, Kim NH, Choi KC.
    Korean J Intern Med; 2002 Jun; 17(2):114-21. PubMed ID: 12164088
    [Abstract] [Full Text] [Related]

  • 8. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 9. Long-term effect of different dialysate calcium concentrations on parathyroid hormone levels in hemodialysis patients.
    Hwang JC, Chen CA, Wang CT, Chen HC.
    Ren Fail; 2008 Nov; 30(10):943-51. PubMed ID: 19016144
    [Abstract] [Full Text] [Related]

  • 10. Calcium, phosphate, and PTH levels in the hemodialysis population: a multicenter study.
    Gallieni M, Cucciniello E, D'Amaro E, Fatuzzo P, Gaggiotti A, Maringhini S, Rotolo U, Brancaccio D, Collaborating nephrologists of the CARDIALISI Study Group.
    J Nephrol; 2002 Nov; 15(2):165-70. PubMed ID: 12018633
    [Abstract] [Full Text] [Related]

  • 11. Sevelamer hydrochloride improves hyperphosphatemia in hemodialysis patients with low bone turnover rate and low intact parathyroid hormone levels.
    Kokuho T, Toya Y, Kawaguchi Y, Tamura K, Iwatsubo K, Dobashi Y, Nakazawa A, Takeda H, Iwatsubo M, Hirawa N, Yasuda G, Ohnishi T, Umemura S.
    Ther Apher Dial; 2007 Dec; 11(6):442-8. PubMed ID: 18028171
    [Abstract] [Full Text] [Related]

  • 12. Association of Parameters of Mineral Bone Disorder with Mortality in Patients on Hemodialysis according to Level of Residual Kidney Function.
    Wang M, Obi Y, Streja E, Rhee CM, Lau WL, Chen J, Hao C, Hamano T, Kovesdy CP, Kalantar-Zadeh K.
    Clin J Am Soc Nephrol; 2017 Jul 07; 12(7):1118-1127. PubMed ID: 28487345
    [Abstract] [Full Text] [Related]

  • 13. The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients.
    Noordzij M, Korevaar JC, Boeschoten EW, Dekker FW, Bos WJ, Krediet RT, Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD) Study Group.
    Am J Kidney Dis; 2005 Nov 07; 46(5):925-32. PubMed ID: 16253734
    [Abstract] [Full Text] [Related]

  • 14. Phosphorus control in peritoneal dialysis patients.
    Yavuz A, Ersoy FF, Passadakis PS, Tam P, Evaggelos DM, Katopodis KP, Ozener C, Akçiçek F, Camsari T, Ateş K, Ataman R, Vlachojannis GJ, Dombros NA, Utaş C, Akpolat T, Bozfakioğlu S, Wu G, Karayaylali I, Arinsoy T, Stathakis CP, Yavuz M, Tsakiris DJ, Dimitriades AC, Yilmaz ME, Gültekin M, Süleymanlar G, Oreopoulos DG.
    Kidney Int Suppl; 2008 Apr 07; (108):S152-8. PubMed ID: 18379539
    [Abstract] [Full Text] [Related]

  • 15. Serum phosphate and calcium should be primarily and consistently controlled in prevalent hemodialysis patients.
    Taniguchi M, Fukagawa M, Fujii N, Hamano T, Shoji T, Yokoyama K, Nakai S, Shigematsu T, Iseki K, Tsubakihara Y, Committee of Renal Data Registry of the Japanese Society for Dialysis Therapy.
    Ther Apher Dial; 2013 Apr 07; 17(2):221-8. PubMed ID: 23551679
    [Abstract] [Full Text] [Related]

  • 16. Comparisons between oral pulse alfacalcidol therapy and daily therapy in maintenance hemodialysis patients with secondary hyperparathyroidism: a randomized, controlled, and multicenter study.
    Gu Y, Ding F, Chen N, Mei CL, Qian JQ, Wang XY, Shi W, Hou FF, Li XW, Wang M, Chen YP.
    Ren Fail; 2005 Apr 07; 27(2):205-12. PubMed ID: 15807187
    [Abstract] [Full Text] [Related]

  • 17. High alkaline phosphatase and low intact parathyroid hormone associate with worse clinical outcome in peritoneal dialysis patients.
    Chen Z, Zhang X, Han F, Xie X, Hua Z, Huang X, Lindholm B, Haarhaus M, Stenvinkel P, Qureshi AR, Chen J.
    Perit Dial Int; 2021 Mar 07; 41(2):236-243. PubMed ID: 32363998
    [Abstract] [Full Text] [Related]

  • 18. Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study.
    Naves-Díaz M, Passlick-Deetjen J, Guinsburg A, Marelli C, Fernández-Martín JL, Rodríguez-Puyol D, Cannata-Andía JB.
    Nephrol Dial Transplant; 2011 Jun 07; 26(6):1938-47. PubMed ID: 20513773
    [Abstract] [Full Text] [Related]

  • 19. Secondary hyperparathyroidism and risk factors in patients undergoing peritoneal dialysis in a tertiary hospital.
    Suwan N.
    J Med Assoc Thai; 2011 Sep 07; 94 Suppl 4():S101-5. PubMed ID: 22043575
    [Abstract] [Full Text] [Related]

  • 20. Can calcium, phosphate, calcium phosphate product and intact parathyroid hormone levels be appropriately controlled in dialysis patients?
    Deger SM, Mutluay R, Derici U, Mandiralioglu F, Arinsoy T, Sindel S.
    Med Princ Pract; 2011 Sep 07; 20(1):85-9. PubMed ID: 21160221
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.